Noxopharm Limited (NOXOF)
USD 0.05
(0.0%)
USD 0.05
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 6.78 Million AUD | -33.02% |
| 2023 | 10.12 Million AUD | -61.91% |
| 2022 | 26.59 Million AUD | -44.43% |
| 2021 | 47.85 Million AUD | 138.47% |
| 2020 | 20.06 Million AUD | 366.63% |
| 2019 | 4.3 Million AUD | -70.44% |
| 2018 | 14.54 Million AUD | 414.37% |
| 2017 | 2.82 Million AUD | 776.45% |
| 2016 | 322.72 Thousand AUD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q4 | 6.78 Million AUD | 0.0% |
| 2024 Q3 | 6.78 Million AUD | -5.2% |
| 2024 Q2 | 7.15 Million AUD | 0.0% |
| 2024 Q1 | 7.15 Million AUD | -29.35% |
| 2024 FY | 6.78 Million AUD | -33.02% |
| 2023 Q2 | 21.91 Million AUD | 0.0% |
| 2023 Q4 | 10.12 Million AUD | 0.0% |
| 2023 FY | 10.12 Million AUD | -61.91% |
| 2023 Q1 | 21.91 Million AUD | -17.59% |
| 2023 Q3 | 10.12 Million AUD | -53.79% |
| 2022 Q2 | 35.98 Million AUD | 0.0% |
| 2022 Q4 | 26.59 Million AUD | 0.0% |
| 2022 FY | 26.59 Million AUD | -44.43% |
| 2022 Q1 | 35.98 Million AUD | -24.79% |
| 2022 Q3 | 26.59 Million AUD | -26.11% |
| 2021 Q1 | 36.09 Million AUD | 79.85% |
| 2021 FY | 47.85 Million AUD | 138.47% |
| 2021 Q4 | 47.85 Million AUD | 0.0% |
| 2021 Q3 | 47.85 Million AUD | 32.59% |
| 2021 Q2 | 36.09 Million AUD | 0.0% |
| 2020 Q1 | 3.54 Million AUD | -17.51% |
| 2020 Q3 | 20.06 Million AUD | 465.68% |
| 2020 Q2 | 3.54 Million AUD | 0.0% |
| 2020 FY | 20.06 Million AUD | 366.63% |
| 2020 Q4 | 20.06 Million AUD | 0.0% |
| 2019 Q1 | 11.13 Million AUD | -23.5% |
| 2019 Q2 | 11.13 Million AUD | 0.0% |
| 2019 Q3 | 4.3 Million AUD | -61.36% |
| 2019 FY | 4.3 Million AUD | -70.44% |
| 2019 Q4 | 4.3 Million AUD | -0.0% |
| 2018 Q3 | 14.54 Million AUD | 164.82% |
| 2018 FY | 14.54 Million AUD | 414.37% |
| 2018 Q1 | 5.49 Million AUD | 94.24% |
| 2018 Q2 | 5.49 Million AUD | 0.0% |
| 2018 Q4 | 14.54 Million AUD | 0.0% |
| 2017 Q1 | 4.52 Million AUD | 1302.57% |
| 2017 Q4 | 2.82 Million AUD | 0.0% |
| 2017 Q3 | 2.82 Million AUD | -37.51% |
| 2017 FY | 2.82 Million AUD | 776.45% |
| 2017 Q2 | 4.52 Million AUD | 0.0% |
| 2016 FY | 322.72 Thousand AUD | 0.0% |
| 2016 Q4 | 322.72 Thousand AUD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Qrons Inc. | 420.00 USD | -1615080.476% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 75.724% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 87.128% |
| Adynxx, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 94.79% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -1311.645% |
| BioStem Technologies, Inc. | 14.56 Million USD | 53.409% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 35.723% |
| Skye Bioscience, Inc. | 11.94 Million USD | 43.187% |
| Rebus Holdings, Inc. | 5000.00 USD | -135575.16% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -246.43% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -293569.177% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -780.271% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -1128.675% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -886.749% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 82.537% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 6.039% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -8784.614% |
| SQZ Biotechnologies Company | 107.18 Million USD | 93.671% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -373.716% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -9274.363% |
| Mesoblast Limited | 667.9 Million USD | 98.984% |
| Marizyme, Inc. | 22.01 Million USD | 69.186% |
| Genus plc | 1.02 Billion USD | 99.341% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -399.411% |
| Pharming Group N.V. | 462.85 Million USD | 98.534% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -104.761% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -1259.364% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -981.939% |
| ContraFect Corporation | 20.67 Million USD | 67.195% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -1637.794% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -1675.03% |
| IMV Inc. | 31.33 Million USD | 78.35% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -63.621% |
| MultiCell Technologies, Inc. | 126.22 USD | -5374450.784% |
| ONE Bio Corp. | 70.08 Million USD | 90.321% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -621.915% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 94.721% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -1471.355% |
| Q BioMed Inc. | 3.51 Million USD | -92.966% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 80.716% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -2496.385% |
| Biomind Labs Inc. | 73.81 Thousand USD | -9089.718% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 98.48% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -368.219% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 77.399% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -147.011% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -160.593% |
| GB Sciences, Inc. | 103.44 Thousand USD | -6458.031% |
| Alpha Cognition Inc. | 2.45 Million USD | -176.643% |
| HST Global, Inc. | 1526.00 USD | -444445.085% |
| CSL Limited | 38.02 Billion USD | 99.982% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -586.638% |
| Halberd Corporation | 10.13 Thousand USD | -66860.399% |
| Enzolytics Inc. | 361.7 Million USD | 98.125% |
| Agentix Corp. | 261.39 Thousand USD | -2495.243% |
| Resverlogix Corp. | 8.11 Million USD | 16.405% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -261.246% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.851% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 85.779% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -960.532% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -29678.14% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 24.197% |
| AVAX Technologies, Inc. | 7.37 Million USD | 8.044% |
| Zenith Capital Corp. | 7410.00 USD | -91448.691% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.8% |
| Ember Therapeutics, Inc. | 184.00 USD | -3686725.0% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -2008.027% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -2495.521% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -631.039% |
| Kadimastem Ltd | 2.3 Million USD | -194.424% |
| Helix BioMedix, Inc. | 3.02 Million USD | -124.25% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -11781.735% |
| LadRx Corporation | 2.3 Million USD | -193.939% |
| Cell Source, Inc. | 195.17 Thousand USD | -3375.802% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -1818.391% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -1818.391% |
| NovAccess Global Inc. | 62.24 Thousand USD | -10797.953% |
| Affymax, Inc. | 7.44 Million USD | 8.857% |
| Itoco Inc. | 1.4 Million USD | -384.529% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -6991.753% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -6299.772% |
| Mobile Lads Corp. | 52.00 USD | -13045588.462% |
| CytoDyn Inc. | 11.13 Million USD | 39.083% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -4644.816% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -37840.481% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -1659.862% |
| SYBLEU INC | 330.46 Thousand USD | -1952.773% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -1556.911% |
| International Stem Cell Corporation | 5.39 Million USD | -25.858% |
| Bioxytran, Inc. | 137.63 Thousand USD | -4828.696% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 54.78% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 59.082% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -8487.035% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -684.542% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 9.754% |
| Neutra Corp. | 2851.00 USD | -237843.108% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 79.066% |
| PureTech Health plc | 693.97 Million USD | 99.022% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 15.95% |
| IXICO plc | 15.84 Million USD | 57.184% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 18.09% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 93.434% |
| CSL Limited | 38.02 Billion USD | 99.982% |
| Cellectis S.A. | 333.99 Million USD | 97.969% |